We used a combination of Medical Subject Headings (MeSH) terms and keywords, including “SGLT2 inhibitors,” “empagliflozin,” “dapagliflozin,” “heart failure,” “cardiovascular outcomes,” and “combination therapy.” Both randomized controlled trials and high-quality observational studies were included, with a focus on human studies published in English. This evidence concerns the gene SLC5A2 and heart failure.